Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Edyta Vieth"'
Autor:
Yesim Gökmen-Polar, Jason D True, Edyta Vieth, Yuan Gu, Xiaoping Gu, Guihong D Qi, Amber L Mosley, Sunil S Badve
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204658 (2018)
Deleted in Liver Cancer-1 (DLC1), a member of the RhoGAP family of proteins, functions as a tumor suppressor in several cancers including breast cancer. However, its clinical relevance is unclear in breast cancer. In this study, expression of DLC1 wa
Externí odkaz:
https://doaj.org/article/cd563584e9fc4422a41fbd701a8a070e
Publikováno v:
Oncotarget
// Horacio Cardenas 1 , Janice Zhao 2 , Edyta Vieth 3 , Kenneth P. Nephew 4 , Daniela Matei 1, 5, 6 1 Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Chicago, IL, USA 2 Oakland University William Beaumont
Autor:
Sarath Chandra Janga, Yaseswini Neelamraju, Xiaoping Gu, Edyta Vieth, Sunil Badve, Yuan Gu, Gouthami Nallamothu, Yesim Gökmen-Polar, Chirayu P. Goswami, Michael Ryan
Publikováno v:
EMBO reports. 20
The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high le
Autor:
Yesim, Gökmen-Polar, Yaseswini, Neelamraju, Chirayu P, Goswami, Yuan, Gu, Xiaoping, Gu, Gouthami, Nallamothu, Edyta, Vieth, Sarath C, Janga, Michael, Ryan, Sunil S, Badve
Publikováno v:
EMBO reports. 20(2)
The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial‐to‐mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that hig
Autor:
Daniela Matei, Horacio Cardenas, Kenneth P. Nephew, Jiyoon Lee, Yunlong Liu, Mathew Segar, Edyta Vieth
Publikováno v:
Epigenetics. 9:1461-1472
A key step in the process of metastasis is the epithelial-to-mesenchymal transition (EMT). We hypothesized that epigenetic mechanisms play a key role in EMT and to test this hypothesis we analyzed global and gene-specific changes in DNA methylation d
Autor:
Yuan Gu, Jason D. True, Guihong D. Qi, Edyta Vieth, Yesim Gökmen-Polar, Sunil Badve, Xiaoping Gu, Amber L. Mosley
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0204658 (2018)
PLoS ONE
PLoS ONE
Deleted in Liver Cancer-1 (DLC1), a member of the RhoGAP family of proteins, functions as a tumor suppressor in several cancers including breast cancer. However, its clinical relevance is unclear in breast cancer. In this study, expression of DLC1 wa
Autor:
Jason D. True, Amber L. Mosley, Guihong D. Qi, Edyta Vieth, Xiaoping Gu, Yuan Gu, Sunil Badve, Yesim Gökmen-Polar
Publikováno v:
Cancer Research. 78:2695-2695
Deleted in Liver Cancer-1 (DLC1), a member of the RhoGAP family of proteins, functions as a tumor suppressor in several cancers including breast cancer. However, its clinical relevance is unclear in breast cancer. In this study, expression of DLC1 wa
Autor:
Yesim Gökmen-Polar, Yuan Gu, Sarath Chandra Janga, Edyta Vieth, Yaseswini Neelamraju, Sunil Badve, Xiaoping Gu, Gouthami Nallamothu, Chirayu Goswami, Michael Ryan
Publikováno v:
Cancer Research. 78:P5-04
Background: Epithelial-to-Mesenchymal Transition (EMT)is postulated to be an important step in cancer progression and controlled by multiple mechanisms including EMT transcription factors (EMT-TFs) and splicing factors such as Epithelial Splicing Reg
Autor:
Jie Zhang, Thomas A. Gardner, Sudhanshu P. Raikwar, Kyung Hee Bae, Xiong Li, Sang Jin Lee, Huanling Gao, Chinghai Kao, Meei Huey Jeng, Yan Ping Zhang, Edyta Vieth, Dale VanderPutten, Gary D. Hutchins
Publikováno v:
Molecular Cancer Therapeutics. 4:1850-1859
The breast-specific antigen α-lactalbumin is expressed in >60% of breast cancer tissues. To evaluate the effect of gene therapy for breast cancer by controlling adenovirus replication with human α-lactalbumin promoter, we investigated the activity
Publikováno v:
Cancer Research. 77:1226-1226
Background: Metastasis is the principal cause of morbidity and mortality from breast cancer. Although current therapies are effective in early-stage of breast cancer, resistance to therapy is common leading to the development of metastasis. The commo